Skip to main content
. Author manuscript; available in PMC: 2022 Jun 21.
Published in final edited form as: Am J Nephrol. 2022 Feb 28;53(2-3):226–239. doi: 10.1159/000521386

Table 4.

Multi-step multivariable linear regression analyses for harmonized serum phosphate levels

Model 1 Model 2 Model 3 Model 4
Difference between CRIC and CKD-JAC at each eGFR category [vs CKD-JAC]* [≤20] 0.98 (0.85, 1.11) 0.89 (0.77, 1.03) 0.87 (0.73, 1.00) 0.74 (0.60, 0.88)
[21 - 30] 0.77 (0.70, 0.84) 0.68 (0.61, 0.76) 0.67 (0.59, 0.74) 0.62 (0.55, 0.70)
[31 - 40] 0.63 (0.56, 0.70) 0.55 (0.47, 0.62) 0.52 (0.45, 0.59) 0.53 (0.46, 0.61)
[41 - 50] 0.53 (0.46, 0.61) 0.45 (0.37, 0.53) 0.42 (0.34, 0.50) 0.46 (0.38, 0.54)
[>50] 0.48 (0.37, 0.60) 0.37 (0.25, 0.49) 0.34 (0.22, 0.46) 0.42 (0.30, 0.54)
eGFR [≤20] 0.49 (0.38, 0.60) 0.48 (0.37, 0.59) 0.49 (0.37, 0.60) 0.62 (0.50, 0.74)
[21 - 30] 0.15 (0.04, 0.26) 0.14 (0.03, 0.25) 0.14 (0.02, 0.25) 0.22 (0.11, 0.34)
[31 - 40] 0.06 (−0.05, 0.17) 0.05 (−0.06, 0.16) 0.05 (−0.06, 0.16) 0.10 (−0.01, 0.21)
[41 - 50] 0.03 (−0.08, 0.15) 0.01 (−0.10, 0.13) 0.01 (−0.10, 0.13) 0.05 (−0.07, 0.17)
[>50] Ref. Ref. Ref. Ref.
Phosphate binders [yes] 0.06 (0.00, 0.12) 0.08 (0.02, 0.13) 0.06 (−0.00, 0.12) 0.06 (0.01, 0.12)
Active vitamin D [yes] 0.03 (−0.03, 0.09) 0.03 (−0.03, 0.09) 0.00 (−0.06, 0.06) 0.00 (−0.06, 0.06)
log(25OHD) (/S.D.) −0.01 (−0.03, 0.01) −0.02 (−0.03, 0.00) −0.03 (−0.04, −0.01) −0.03 (−0.04, −0.00)
log(DHQ calcium) (/S.D.) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)
log(uPhos/uCr) (/S.D.) 0.08 (0.06, 0.09) 0.07 (0.06, 0.09) −0.01 (−0.04, 0.03)
log(uPhos/uCr) x eGFR [≤20] 0.27 (0.21, 0.33)
[21 - 30] 0.13 (0.09, 0.18)
[31 - 40] 0.06 (0.02, 0.11)
[41 - 50] 0.03(−0.01, 0.08)
[>50] Ref.
log(PTH) (/S.D.) −0.05 (−0.07, −0.03) −0.06 (−0.07, −0.04)
log(intact FGF23) (/S.D.) 0.06 (0.03, 0.08) 0.05 (0.03, 0.08)
*

There was a significant interaction between CRIC x eGFR in every model.

Data are expressed as mean (95% confidence interval). Abbreviations: eGFR, estimated glomerular filtration rate; 25OHD, 25-hydroxyvitamin D; DHQ, dietary health questionnaire; uPhos/uCr, urine phosphate-to-creatinine ratio; PTH, parathyroid hormone; FGF23, fibroblast growth factor-23; S.D., standard deviation. Bold values denote statistical significance of p < 0.05.

Model 1: Adjusted for demographics (age, gender, urine albumin-to-creatinine ratio, diabetes, and facilities as cluster) + Nutrition (albumin and body mass index category) + Medication (active vitamin D and phosphate binders) + 25OHD

Model 2: Model 1 + calcium intake (DHQ calcium) + phosphorus intake (DHQ phosphorus + pops frequency (3a) or uPhos/uCr (3b))

Model 3: Model 2 + PTH + FGF23

Model 4: Model 3 + interaction term of uPhos/uCr x eGFR